Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02648295

Enrollment

Registered

2016-01-07

Start date

2015-12-31

Completion date

2016-10-31

Last updated

2017-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status Post Total Hip and Knee Arthroplasty

Brief summary

Blood management is an important part of successful total joint replacement. Loss of blood and transfusion can lead to poor outcomes for patients. The use of tranexamic acid (TXA) has become a standard component to many blood management programs. It is used to treat or prevent excessive blood loss during surgery and in various medical conditions such as excessive bleeding or hemorrhage. A normal body process prevents blood clots that occur naturally from growing and causing problems. When this process becomes overactive it can result in excessive bleeding, leading to increased blood transfusions. The proposed study seeks to evaluate the relationship between TXA and thromboelastogram (TEG) results.

Interventions

PROCEDUREEffects of IV TXA on TEG in patients undergoing THA or TKA

Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Primary total hip and knee arthroplasty patients presenting to WVU Center for Joint Replacement * 40-90 years old

Exclusion criteria

* Known coagulopathy * History of venothrombotic event * Unstable angina * Recent Myocardial infarction (MI) * History of bleeding events * History of chronic anemia * Preoperative anemia * Current use of blood thinners including aspirin

Design outcomes

Primary

Measure	Time frame	Description
All time measurements which indicate various aspects of clotting cascade	3 months	Data derived from the TEG which includes R, MA, LY30 (R = clotting factors, MA clot strength and platelet function and LY30 is fibrinolysis).

Secondary

Measure	Time frame	Description
Blood loss and transfusions	3 months	Estimated and Calculated blood loss and transfusion requirements

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026